Is PRLD or PRTC more undervalued in 2026?

CirclFi compares Prelude Therapeutics Incorporat (PRLD) and PureTech Health plc (PRTC) using 13 institutional-grade valuation models. PRLD has a Quality of Company score of 5.9/10 while PRTC scores 5.4/10.

Which is a better buy — PRLD or PRTC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PRLD and PRTC valuations compare?

PRLD at $3.93 and PRTC at $17.25 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PRLD vs PRTC Valuation Comparison 2026 — Intrinsic Value Analysis

PRLD

Biotechnology

Prelude Therapeutics Incorporat

Quality

5.9

out of 10

Value Trap

SAFE

Price

$3.93

Last close

Models

9/13

Active

PRTC

Biotechnology

PureTech Health plc

Quality

5.4

out of 10

Value Trap

LOW

Price

$17.25

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	PRLD Fair Value	PRLD Upside	PRTC Fair Value	PRTC Upside
Bayesian DCF	Intrinsic	$1.12	-71.6%	$19.06	+10.5%
Earnings Power Value	Intrinsic	—	—	$2.12	-88.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.75	-55.5%	$11.83	-31.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PRLD vs PRTC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PRLD vs PRTC — Which Stock Is More Undervalued?

PRLD scores higher with a 5.9/10 quality rating vs PRTC's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Prelude Therapeutics Incorporat (PRLD) and PureTech Health plc (PRTC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PRLD currently trades at $3.93 with a QOC of 5.9/10, while PRTC trades at $17.25 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).